This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Apricus And Laboratoires Majorelle Sign Exclusive License Agreement To Market Topical Erectile Dysfunction Cream Vitaros(R) In France, Monaco And Certain African Countries

SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus" or the "Company") (Nasdaq:APRI) ( www.apricusbio.com ), announced today that Apricus signed an exclusive license agreement with Laboratoires Majorelle ("Majorelle") to market Vitaros ®, its topical on-demand product for the treatment of erectile dysfunction ("ED"), in France, Monaco and certain African countries (the "Territory").

Under the terms of the agreement, Apricus is eligible to receive up to $4 million from Majorelle in upfront and regulatory milestone payments. Apricus is also eligible to receive up to approximately $21 million in milestone payments on future sales, plus double-digit tiered royalties based on Majorelle's net sales of the product in the Territory. In exchange, Majorelle will have the exclusive right to commercialize Vitaros ® in the Territory. In addition, Majorelle has agreed to minimum marketing commitments for Vitaros ®, including the expansion of its existing sales force in France.

"Given their extensive depth and experience in the urology market, Majorelle is well equipped to bring the unique benefits of Vitaros ® to patients and health care providers in these important territories," said Richard Pascoe, Chief Executive Officer of Apricus. "With their strong and growing commercial organization, led by a highly experienced management team, and their impressive financial commitment to marketing Vitaros ®, we look forward to Majorelle's successful launch of the only topical on-demand ED treatment in France and other French speaking countries."

"We're very excited to have an opportunity to work with Apricus and market Vitaros ® in France, Monaco and Africa," said Majorelle's Chairman, Mehdi El Glaoui. "We have a strong urology presence in France, one of the largest ED markets in Europe, and we are committed to a robust launch of Vitaros ® with an experienced team capable of driving sales and expanding the market. With national phase approval on the horizon, we are well positioned to bring this best in class ED treatment to patients."

Vitaros ® is currently partnered in key markets, including with Takeda in the United Kingdom, Sandoz in Germany, Bracco in Italy, Majorelle in France, Monaco and certain African countries, and Abbott in Canada. Apricus has received and reviewed multiple bids for commercialization rights for Vitaros ® in the remaining un-partnered territories in Europe and it expects to announce additional licensing transactions by year-end 2013.

About Vitaros ®

Vitaros ® has been approved for the treatment of ED by the European Health Authorities and by Health Canada. Vitaros ® is a topically-applied cream formulation of alprostadil, a vasodilator, combined with our proprietary permeation enhancer DDAIP.HCl, which directly increases blood flow to the penis, causing an erection. Alprostadil is a widely accepted alternative to the PDE-5 inhibitors for difficult to treat patients, and Vitaros ®, which was determined to be safe and effective by the European Health Authorities and previously by Health Canada, offers greater market opportunity due to its patient-friendly form versus other alprostadil dosage forms and also relative to oral ED products. With nearly 150 million men worldwide who suffer from ED and an ED market size of approximately $1 billion in revenue in Europe alone, Vitaros ® represents a major market opportunity for Apricus and its commercial partners given its unique product profile and its potential to treat a large underserved population.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets through its licensing partners innovative treatments that have the potential to help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros ®, for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Bracco SpA and Laboratoires Majorelle. Femprox ®, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed a nearly 400-subject proof-of-concept study.

For further information on Apricus, visit http://www.apricusbio.com .

About Laboratoires Majorelle

Laboratoires Majorelle was founded in 2001 and is headquartered in Paris, France. Majorelle has a strong, well-experienced commercialization team dedicated to urology and reproductive products for both males and females.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs